<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Ann Card Anaesth</journal-id>
      <journal-id journal-id-type="iso-abbrev">Ann Card Anaesth</journal-id>
      <journal-id journal-id-type="publisher-id">ACA</journal-id>
      <journal-title-group>
        <journal-title>Annals of Cardiac Anaesthesia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0971-9784</issn>
      <issn pub-type="epub">0974-5181</issn>
      <publisher>
        <publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name>
        <publisher-loc>India</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27716709</article-id>
      <article-id pub-id-type="pmc">5070338</article-id>
      <article-id pub-id-type="publisher-id">ACA-19-737</article-id>
      <article-id pub-id-type="doi">10.4103/0971-9784.191575</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Valve-in-valve-in homograft: A case of a repeat transcatheter aortic valve replacement in a patient with an aortic homograft</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Hollander</surname>
            <given-names>Kimberly Naden</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Montealegre-Gallegos</surname>
            <given-names>Mario</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mahmood</surname>
            <given-names>Feroze</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
      </contrib-group>
      <aff id="aff1">Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA</aff>
      <author-notes>
        <corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Feroze Mahmood, Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA. E-mail: <email xlink:href="fmahmood@bidmc.harvard.edu">fmahmood@bidmc.harvard.edu</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Oct-Dec</season>
        <year>2016</year>
      </pub-date>
      <volume>19</volume>
      <issue>4</issue>
      <fpage>737</fpage>
      <lpage>739</lpage>
      <history>
        <date date-type="received">
          <day>24</day>
          <month>4</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>03</day>
          <month>8</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright: &#xA9; 2016 Annals of Cardiac Anaesthesia</copyright-statement>
        <copyright-year>2016</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0">
          <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>In recent years, the use of transcatheter aortic valve replacement (TAVR) has extended beyond the treatment of native aortic valve stenosis in patients with high surgical risk. TAVR is increasingly being performed for bioprosthetic aortic valve failure, i.e., the valve-in-valve (VIV) procedure. Establishing the success of a VIV procedure can be challenging in these cases. Furthermore, the limited availability of prostheses sizes further complicates the management of these patients. We present an unusual case of a repeat TAVR in a patient who previously had a VIV procedure in an aortic homograft.</p>
      </abstract>
      <kwd-group>
        <kwd>Aortic homograft</kwd>
        <kwd>Transcatheter aortic valve replacement</kwd>
        <kwd>Transesophageal echocardiography</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="sec1-1">
      <title>INTRODUCTION</title>
      <p>Transcatheter aortic valve replacement (TAVR) is increasingly being used for the treatment of severe native aortic valve stenosis in patients with a high surgical risk. TAVR has extended beyond the treatment of native aortic valve stenosis; it has also been performed in some cases of bioprosthetic aortic valve failure, i.e., the valve-in-valve (VIV) procedure. Evaluating the success of a VIV procedure can be challenging, since elevated transvalvular gradients occur frequently after VIV when compared to TAVR in native valves. We present a case of a repeat TAVR in a patient who previously had a VIV procedure in an aortic homograft.</p>
    </sec>
    <sec id="sec1-2">
      <title>CASE REPORT</title>
      <p>A 53-year-old man presented to our institution with increasing shortness of breath. The patient had a history of aortic homograft surgery (21 mm) 16 years previously due to endocarditis, as well as hepatitis C and cirrhosis. He was found to have thickened bioprosthetic aortic valve leaflets with severe aortic stenosis (peak gradient of 93 mmHg and mean gradient of 56 mmHg) and severe aortic regurgitation. Given the patient's comorbidities, he was not considered a candidate for redo surgical aortic valve replacement, and he underwent urgent TAVR with a SAPIEN 23 mm valve (Edwards Lifesciences Corporation, Irvine, CA, USA). After device deployment, there was an improvement in the hemodynamics with mild residual stenosis. Transthoracic echocardiography (TTE) on postprocedure day 3 demonstrated a transaortic gradient that was higher than expected but improved when compared to preprocedure (peak gradient of 57 mmHg and mean gradient of 38 mmHg). The patient noted a significant improvement in his symptoms at 1-month follow-up. A TTE performed 1 year after TAVR showed no significant change.</p>
      <p>Two years post-TAVR, the patient returned to our institution with worsening shortness of breath. TTE showed an increase in transvalvular gradients without aortic regurgitation. The patient underwent repeat TAVR with a 23 mm Edwards SAPIEN XT valve. Predeployment transesophageal echocardiography (TEE) showed severely thickened aortic valve leaflets [<xref ref-type="fig" rid="F1">Figure 1</xref>] with severe stenosis (peak gradient of 65 mmHg, mean gradient of 36 mmHg, and valve area of 0.57 cm<sup>2</sup>) [Figures <xref ref-type="fig" rid="F2">2</xref> and <xref ref-type="fig" rid="F3">3</xref>]. After deployment, TEE showed a well-functioning TAVR with a peak gradient of 55 mmHg and no paravalvular leaks. The patient's symptoms improved and he was discharged on postprocedure day 3.</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Preoperative mid-esophageal aortic valve long-axis view demonstrating a significant calcification of the aortic homograft generating severe aortic stenosis</p>
        </caption>
        <graphic xlink:href="ACA-19-737-g001"/>
      </fig>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Continuous wave Doppler of the aortic valve demonstrating an increased mean pressure gradient with an aortic valve area of 0.57 cm<sup>2</sup></p>
        </caption>
        <graphic xlink:href="ACA-19-737-g002"/>
      </fig>
      <fig id="F3" position="float">
        <label>Figure 3</label>
        <caption>
          <p>Deep transgastric long-axis view demonstrating turbulent flow across the aortic valve on color flow Doppler</p>
        </caption>
        <graphic xlink:href="ACA-19-737-g003"/>
      </fig>
    </sec>
    <sec sec-type="discussion" id="sec1-3">
      <title>DISCUSSION</title>
      <p>In patients at high risk of surgery, VIV implantation can be a useful alternative for the management of bioprosthetic aortic valve failure. However, VIV procedures are associated with several technical challenges.[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref3" ref-type="bibr">3</xref><xref rid="ref4" ref-type="bibr">4</xref>] It has been described that elevated postprocedural gradients (mean gradient of &gt;20 mmHg) occurred in approximately 28% of cases after VIV procedures.[<xref rid="ref1" ref-type="bibr">1</xref>] Elevated transvalvular gradients occur frequently after VIV when compared to TAVR in native valves, possibly because of underexpansion of the prosthesis inside the surgical bioprosthetic valve.[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref3" ref-type="bibr">3</xref>] This underexpansion is particularly relevant with a small bioprosthesis.[<xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref4" ref-type="bibr">4</xref>] Given our patient's small 21 mm aortic homograft, the elevated postprocedural gradients were accepted, knowing that a smaller starting orifice would lead to higher gradients.</p>
      <p>In this case, the patient had a repeat TAVR 2 years after the first procedure due to persistently elevated and worsening transvalvular gradients with recurrent symptoms of severe aortic stenosis.</p>
      <p>There have been some previous reports of repeat VIV procedures for treating failed surgically implanted valves, but these serial TAVRs were done immediately during the initial VIV procedure when the first valve deployment was not successful.[<xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref6" ref-type="bibr">6</xref>] Furthermore, this patient had an aortic homograft, which accounts for only 7% of the surgical valves in the Global VIV Registry.[<xref rid="ref2" ref-type="bibr">2</xref>] Given the feasibility of VIV procedures, and with high postprocedural gradients being an accepted limitation, cases of patients with prior VIV procedure needing repeat TAVR will likely become more frequent in the future.</p>
      <sec id="sec2-1">
        <title>Financial support and sponsorship</title>
        <p>Nil.</p>
      </sec>
      <sec id="sec2-2">
        <title>Conflicts of interest</title>
        <p>There are no conflicts of interest.</p>
      </sec>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="ref1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dvir</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Webb</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Brecker</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bleiziffer</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hildick-Smith</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Colombo</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: Results from the global valve-in-valve registry</article-title>
          <source>Circulation</source>
          <year>2012</year>
          <volume>126</volume>
          <fpage>2335</fpage>
          <lpage>44</lpage>
          <pub-id pub-id-type="pmid">23052028</pub-id>
        </element-citation>
      </ref>
      <ref id="ref2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Webb</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Dvir</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Transcatheter aortic valve replacement for bioprosthetic aortic valve failure: The valve-in-valve procedure</article-title>
          <source>Circulation</source>
          <year>2013</year>
          <volume>127</volume>
          <fpage>2542</fpage>
          <lpage>50</lpage>
          <pub-id pub-id-type="pmid">23797741</pub-id>
        </element-citation>
      </ref>
      <ref id="ref3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dvir</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Webb</surname>
              <given-names>JG</given-names>
            </name>
          </person-group>
          <article-title>Transcatheter aortic valve-in-valve implantation for patients with degenerative surgical bioprosthetic valves</article-title>
          <source>Circ J</source>
          <year>2015</year>
          <volume>79</volume>
          <fpage>695</fpage>
          <lpage>703</lpage>
          <pub-id pub-id-type="pmid">25797021</pub-id>
        </element-citation>
      </ref>
      <ref id="ref4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Noorani</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Radia</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bapat</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Challenges in valve-in-valve therapy</article-title>
          <source>J Thorac Dis</source>
          <year>2015</year>
          <volume>7</volume>
          <fpage>1501</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">26543595</pub-id>
        </element-citation>
      </ref>
      <ref id="ref5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bagur</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Dumont</surname>
              <given-names>&#xC9;</given-names>
            </name>
            <name>
              <surname>Doyle</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>De Larochelli&#xE8;re</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Rod&#xE9;s-Cabau</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Transcatheter aortic valve-in-valve-in-valve implantation for a failed xenograft</article-title>
          <source>Ann Thorac Surg</source>
          <year>2012</year>
          <volume>93</volume>
          <fpage>647</fpage>
          <lpage>50</lpage>
          <pub-id pub-id-type="pmid">22269731</pub-id>
        </element-citation>
      </ref>
      <ref id="ref6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nuis</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Benitez</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Nader</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Perez</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>de Marchena</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Dager</surname>
              <given-names>AE</given-names>
            </name>
          </person-group>
          <article-title>Valve-in-valve-in-valve transcatheter aortic valve implantation to treat a degenerated surgical bioprosthesis in a subaortic position</article-title>
          <source>Tex Heart Inst J</source>
          <year>2013</year>
          <volume>40</volume>
          <fpage>323</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">23914032</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
